GSK plc

1,890pAs of Sun 8 Nov 2026, 12:00 UTC
LSE:GSKHealthcare
Ctry United Kingdom
PE (Fwd) •••
TSR 10Y CAGR 6.30%
Div yield 3.81%
ROE 28.27%
Drug Manufacturers (General)
Beta (5Y) 0.28
PE TTM 17.72
TSR TTM 9.93%
Mkt cap £75.77B
ROIC 24.61%
SE Grade™
Value
Quality
Moat
Consensus
Reference
2,072p
9.61%
(21.55%)
Hold 5|2|7|7|6
4Q25
1Q26
2Q26
3Q26
Earnings per share£
20.43
20.30
20.52
22.09
17.23%
14.88%
10.45%
15.44%
Revenue£B
8.504
8.257
8.063
7.844
0.76%
(1.34%)
(2.32%)
(3.50%)
Peers (US$102.0B)
Cap (US$)
PE
290.7B
26.20x
40.09B
18.72x
112.7B
24.22x
Capital
TTM
5Y
10Y
Leveragex
1.819
(0.036)
(0.034)
EBIT/Intx
1.418
0.083
0.102
Own earn%
408.33
(145.77)
(113.55)
Sh yield%
48.62
25.07
21.32
Owners
Insiders/Inst%
12.36
78.85
Short interest%
2.62
SBC / revenue%
1.01
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
13–20
$1 testx
—
Incr. ROIC%
24

GSK plc researches, develops and manufactures vaccines, specialty medicines and general medicines to prevent and treat disease in the United Kingdom, the United States and internationally. Its specialty medicines cover HIV, oncology, respiratory and immunology, while its vaccines target diseases including shingles, meningitis, RSV and influenza, and its general medicines treat asthma, COPD and bacterial infection.